About Infinity Pharmaceuticals (NASDAQ:INFI)
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:INFI
CUSIP45665G30
Phone617-453-1000
Debt
Debt-to-Equity RatioN/A
Current Ratio5.04%
Quick Ratio5.04%
Price-To-Earnings
Trailing P/E Ratio-2.64
Forward P/E Ratio-2.99
P/E GrowthN/A
Sales & Book Value
Annual Sales$6 million
Price / Sales19.14
Cash FlowN/A
Price / CashN/A
Book Value$0.94 per share
Price / Book2.35
Profitability
EPS (Most Recent Fiscal Year)($0.83)
Net Income$-41,830,000.00
Net MarginsN/A
Return on Equity-71.57%
Return on Assets-52.61%
Miscellaneous
Employees22
Outstanding Shares51,960,000
Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions
What is Infinity Pharmaceuticals' stock symbol?
Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."
How were Infinity Pharmaceuticals' earnings last quarter?
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) announced its quarterly earnings results on Thursday, March, 15th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.25) by $0.11. View Infinity Pharmaceuticals' Earnings History.
Who are some of Infinity Pharmaceuticals' key competitors?
Some companies that are related to Infinity Pharmaceuticals include Molecular Templates (MTEM), Ardelyx (ARDX), MannKind (MNKD), CTI BioPharma (CTIC), Recro Pharma (REPH), Corvus Pharmaceuticals (CRVS), Tyme Technologies (TYME), Calithera Biosciences (CALA), Verona Pharma (VRNA), Fortress Biotech (FBIO), Verastem (VSTM), Tocagen (TOCA), VBI Vaccines (VBIV), Menlo Therapeutics (MNLO), Ra Pharmaceuticals (RARX), POXEL (PXXLF), Xoma (XOMA) and Marinus Pharmaceuticals (MRNS).
Who are Infinity Pharmaceuticals' key executives?
Infinity Pharmaceuticals' management team includes the folowing people:
- Adelene Q. Perkins, Chairman of the Board, Chief Executive Officer (Age 57)
- Lawrence E. Bloch M.D. J.D., President, Principal Financial Officer, Principal Accounting Officer (Age 52)
- William C. Bertrand Jr. Esq., Executive Vice President, General Counsel (Age 52)
- Melissa Hackel, Vice President - Finance
- Joseph Pearlberg M.D. Ph.D., Vice President - Clinical Development
- Norman C. Selby, Lead Outside Independent Director (Age 62)
- David W. Beier J.D., Independent Director
- Jeffrey Berkowitz J.D., Independent Director (Age 49)
- Anthony B. Evnin Ph.D., Independent Director (Age 76)
- Michael G. Kauffman M.D., Ph.D., Independent Director
Has Infinity Pharmaceuticals been receiving favorable news coverage?
News coverage about INFI stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Infinity Pharmaceuticals earned a news impact score of 0.03 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 45.70 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Infinity Pharmaceuticals' major shareholders?
Infinity Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BIOTECHNOLOGY VALUE FUND L P (21.70%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Lawrence E Bloch, Michael C Venuti, Sujay Kango and Value Fund L P Biotechnology. View Institutional Ownership Trends for Infinity Pharmaceuticals.
How do I buy shares of Infinity Pharmaceuticals?
Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Infinity Pharmaceuticals' stock price today?
One share of INFI stock can currently be purchased for approximately $2.21.
How big of a company is Infinity Pharmaceuticals?
Infinity Pharmaceuticals has a market capitalization of $116.39 million and generates $6 million in revenue each year. The biotechnology company earns $-41,830,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Infinity Pharmaceuticals employs 22 workers across the globe.
How can I contact Infinity Pharmaceuticals?
Infinity Pharmaceuticals' mailing address is 784 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]
MarketBeat Community Rating for Infinity Pharmaceuticals (INFI)
MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote "Outperform" if you believe INFI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INFI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Infinity Pharmaceuticals (NASDAQ:INFI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Infinity Pharmaceuticals (NASDAQ INFI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.81%
Institutional Ownership Percentage: 49.77%
Infinity Pharmaceuticals (NASDAQ INFI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/10/2018 | Value Fund L P Biotechnology | Major Shareholder | Buy | 1,510,000 | $1.97 | $2,974,700.00 | |  |
| 3/5/2018 | Adelene Q Perkins | CEO | Sell | 5,000 | $2.78 | $13,900.00 | 607,252 | |
| 12/6/2017 | Lawrence E Bloch | President | Buy | 500,000 | $1.81 | $905,000.00 | 580,944 | |
| 10/4/2017 | Value Fund L P Biotechnology | Insider | Buy | 1,600,046 | $1.26 | $2,016,057.96 | | |
| 3/17/2017 | Michael C Venuti | Director | Sell | 6,250 | $3.48 | $21,750.00 | 50,000 | |
| 1/3/2017 | Value Fund L P Biotechnology | Major Shareholder | Buy | 4,379 | $1.34 | $5,867.86 | | |
| 12/30/2016 | Value Fund L P Biotechnology | Major Shareholder | Buy | 742,401 | $1.34 | $994,817.34 | | |
| 12/20/2016 | Value Fund L P Biotechnology | Major Shareholder | Buy | 654,921 | $1.31 | $857,946.51 | | |
| 12/13/2016 | Sujay Kango | Insider | Sell | 75,000 | $1.28 | $96,000.00 | 50,590 | |
| 12/12/2016 | Sujay Kango | Insider | Sell | 25,009 | $1.30 | $32,511.70 | 50,590 | |
| 12/2/2016 | Value Fund L P Biotechnology | Major Shareholder | Buy | 201,394 | $1.19 | $239,658.86 | | |
| 6/25/2015 | Adelene Q Perkins | CEO | Sell | 5,000 | $10.93 | $54,650.00 | | |
| 6/15/2015 | Vito J Palombella | Insider | Sell | 4,737 | $10.97 | $51,964.89 | | |
| 5/27/2015 | Adelene Q Perkins | CEO | Sell | 10,000 | $12.81 | $128,100.00 | | |
| 5/14/2015 | Adelene Q Perkins | CEO | Sell | 10,000 | $12.18 | $121,800.00 | | |
| 3/16/2015 | Adelene Q Perkins | CEO | Sell | 20,000 | $16.00 | $320,000.00 | | |
| 1/29/2015 | Adelene Q Perkins | CEO | Sell | 20,000 | $14.83 | $296,600.00 | | |
| 12/15/2014 | Vito J Palombella | Insider | Sell | 4,737 | $16.32 | $77,307.84 | | |
| 11/26/2014 | Vito J Palombella | Insider | Sell | 4,736 | $15.00 | $71,040.00 | | |
| 9/30/2014 | Anthony B Evnin | Director | Sell | 112,451 | $13.56 | $1,524,835.56 | | |
| 9/3/2014 | Vito J Palombella | Insider | Sell | 9,472 | $15.39 | $145,774.08 | | |
| 11/27/2013 | Anthony B Evnin | Director | Sell | 163,864 | $14.82 | $2,428,464.48 | | |
| 9/13/2013 | Adelene Perkins | CEO | Sell | 45,000 | $20.72 | $932,400.00 | 447,535 | |
| 6/20/2013 | Vito J Palombella | Insider | Sell | 23,150 | $18.53 | $428,969.50 | | |
| 11/26/2012 | Christopher M Lindblom | Insider | Sell | 13,885 | $25.73 | $357,261.05 | | |
| 9/7/2012 | Co Beacon | Major Shareholder | Buy | 5,416,565 | $14.50 | $78,540,192.50 | | |
(Data available from 1/1/2013 forward)
Infinity Pharmaceuticals (NASDAQ INFI) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Why Is Infinity Pharmaceuticals (INFI) Down 18.3% Since its Last Earnings Report?
finance.yahoo.com - April 16 at 8:16 AM |
 | BRIEF-BVF Partners Reports 21.7 Pct Stake In Infinity Pharmaceuticals As Of April 10
www.reuters.com - April 13 at 8:19 AM |
| Why Infinity Pharmaceuticals (INFI) Could Shock the Market Soon
finance.yahoo.com - April 12 at 5:38 PM |
 | Insider Buying: Infinity Pharmaceuticals Inc. (INFI) Major Shareholder Acquires 1,510,000 Shares of Stock
www.americanbankingnews.com - April 11 at 7:09 PM |
| -$0.18 Earnings Per Share Expected for Infinity Pharmaceuticals Inc. (INFI) This Quarter
www.americanbankingnews.com - April 7 at 1:13 AM |
| Zacks Investment Research Upgrades Infinity Pharmaceuticals (INFI) to "Hold"
www.americanbankingnews.com - April 6 at 8:45 PM |
 | Are Options Traders Betting on a Big Move in Infinity Pharmaceuticals (INFI) Stock?
www.zacks.com - March 28 at 8:28 AM |
 | Infinity Pharmaceuticals (INFI) Presents At BioCentury's 25th Annual Future Leaders In The Biotech Industry Conference - Slideshow
seekingalpha.com - March 27 at 5:14 PM |
| Infinity to Present at Two Upcoming Conferences
finance.yahoo.com - March 26 at 5:18 PM |
| Can The Uptrend Continue for Infinity Pharmaceuticals (INFI)?
finance.yahoo.com - March 22 at 8:26 AM |
| Infinity To Present At BioCentury's 25th Annual Future Leaders In The Biotech Industry Conference
finance.yahoo.com - March 21 at 5:37 PM |
| Brokerages Anticipate Infinity Pharmaceuticals Inc. (INFI) Will Announce Earnings of -$0.18 Per Share
www.americanbankingnews.com - March 21 at 1:26 AM |
| William Blair Comments on Infinity Pharmaceuticals Inc.'s Q1 2019 Earnings (INFI)
www.americanbankingnews.com - March 19 at 5:16 AM |
 | Infinity (INFI) Reports Narrower-than-Expected Loss in Q4 - Nasdaq
www.nasdaq.com - March 17 at 8:26 AM |
| Edited Transcript of INFI earnings conference call or presentation 15-Mar-18 8:30pm GMT
finance.yahoo.com - March 16 at 6:29 PM |
| Infinity Pharmaceuticals (INFI) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS
www.americanbankingnews.com - March 16 at 9:44 AM |
 | Infinity Pharmaceuticals Provides Company Update and Reports ... - PR Newswire (press release)
www.prnewswire.com - March 16 at 8:20 AM |
| Infinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 16 at 8:20 AM |
| Infinity Pharmaceuticals Provides Company Update and Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 15 at 6:12 PM |
| Infinity Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - March 15 at 6:12 PM |
| Infinity Pharmaceuticals Announces Additions to Board of Directors ... - PR Newswire (press release)
www.prnewswire.com - March 9 at 8:20 AM |
| Infinity Announces the Date of Its Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast
finance.yahoo.com - March 8 at 6:43 PM |
| Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board
finance.yahoo.com - March 8 at 6:43 PM |
| Infinity Pharmaceuticals Inc. (INFI) CEO Sells $13,900.00 in Stock
www.americanbankingnews.com - March 7 at 7:46 PM |
| Head-To-Head Survey: Immunomedics (IMMU) vs. Infinity Pharmaceuticals (INFI)
www.americanbankingnews.com - March 5 at 11:36 AM |
| Infinity Pharmaceuticals (INFI) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - March 5 at 2:16 AM |
| -$0.25 EPS Expected for Infinity Pharmaceuticals Inc. (INFI) This Quarter
www.americanbankingnews.com - March 3 at 9:10 PM |
 | Notice of Annual General Meeting Copenhagen Stock Exchange:LUN - GlobeNewswire (press release)
globenewswire.com - February 19 at 8:16 AM |
| Infinity Pharmaceuticals Inc. (INFI) Expected to Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - February 15 at 3:16 AM |
| Mid-Morning Market Update: Markets Mostly Lower; Groupon Profit Misses Views
www.nasdaq.com - February 14 at 4:05 PM |
| Infinity Pharmaceuticals (INFI) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 13 at 3:44 PM |
| Infinity To Present At BIO CEO & Investor Conference
finance.yahoo.com - February 5 at 9:34 AM |
| -$0.25 Earnings Per Share Expected for Infinity Pharmaceuticals Inc. (INFI) This Quarter
www.americanbankingnews.com - January 29 at 5:12 AM |
 | Verastem Presents Preclinical Data at ASCO-SITC Highlighting the Synergistic Effects of Duvelisib in Combination with Immune Checkpoint or Co-Stimulatory Antibodies in B Cell ...
www.businesswire.com - January 26 at 3:43 PM |
| Infinity Provides Update on Lead Candidate, Issues 2018 View
www.zacks.com - January 26 at 9:18 AM |
| Stock Review for Biotech's Investors -- Gilead Sciences, ImmunoGen, Incyte, and Infinity Pharma
www.prnewswire.com - January 23 at 5:26 PM |
| Analyzing Iqvia (IQV) and Infinity Pharmaceuticals (INFI)
www.americanbankingnews.com - January 13 at 9:36 PM |
| Infinity Pharmaceuticals Inc. (INFI) Expected to Announce Earnings of -$0.25 Per Share
www.americanbankingnews.com - January 12 at 7:48 AM |
| Parkinson's Drug Hits Shelves, Major Event Awaits ABIO In Mar, FDA Nod For NVRO - Nasdaq
www.nasdaq.com - January 9 at 6:05 AM |
| Infinity Provides Update on IPI-549 Phase 1/1b Study, 2018 Goals and Financial Guidance - PR Newswire (press release)
www.prnewswire.com - January 8 at 11:18 AM |
| Infinity Provides Update on IPI-549 Phase 1/1b Study, 2018 Goals and Financial Guidance
finance.yahoo.com - January 8 at 11:18 AM |
| Infinity To Present At 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 5 at 3:18 PM |
| Analysts Anticipate Infinity Pharmaceuticals Inc. (INFI) to Post -$0.25 EPS
www.americanbankingnews.com - December 9 at 3:12 AM |
| Ismailia National Food Industries : Fairly valued, but don’t skip the other factors
finance.yahoo.com - December 7 at 3:17 PM |
| Infinity Pharmaceuticals Inc. (INFI) President Lawrence E. Bloch Acquires 500,000 Shares
www.americanbankingnews.com - December 7 at 11:30 AM |
| ValuEngine Downgrades Infinity Pharmaceuticals (INFI) to Strong Sell
www.americanbankingnews.com - December 3 at 11:06 AM |
| Options Traders Expect Huge Moves in Infinity Pharmaceuticals (INFI) Stock
finance.yahoo.com - November 15 at 2:59 AM |
| Infinity Pharmaceuticals (INFI) Presents At Society For Immunotherapy Of Cancer - Slideshow
seekingalpha.com - November 14 at 12:59 AM |
| Featured Company News - Infinity Shares Clinical and Translational Data from Monotherapy Dose-Escalation Component of Phase-1/1b Study for IPI-549
finance.yahoo.com - November 13 at 7:56 PM |
| Today’s Research Reports on Stocks to Watch: Infinity Pharmaceuticals and Synergy Pharmaceuticals
finance.yahoo.com - November 13 at 7:56 PM |
Infinity Pharmaceuticals (NASDAQ:INFI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Infinity Pharmaceuticals (NASDAQ:INFI) Income Statement, Balance Sheet and Cash Flow Statement
Infinity Pharmaceuticals (NASDAQ INFI) Stock Chart for Monday, April, 23, 2018
Loading chart…
